Medigene to Present at Upcoming Scientific Conferences
April 17 2024 - 6:00AM
Medigene AG (Medigene or the “Company”, FSE:
MDG1, Prime Standard), an immuno-oncology platform company focusing
on the discovery and development of T cell immunotherapies for
solid tumors, has been invited to present at the CHI's 8th Annual
Immuno-Oncology Summit Europe from April 23-25, 2024, in London,
UK, as well as at the 7th International Neoantigen Summit to be
held in Amsterdam, Netherlands from April 29 - May 1, 2024.
The presentations will be available on
Medigene´s website after the conferences:
https://medigene.com/science/abstracts/
Oral presentation:
CHI's 8th Annual Immuno-Oncology Summit
Europe 2024
https://www.immuno-oncologyeurope.com/Location: Hilton London
Canary Wharf, LondonDate and time: April 25, 2024, 13:15 – 13:45 pm
local timePresenter: Kirsty Crame, MD, VP Clinical Strategy &
DevelopmentSession: Novel approaches targeting solid tumors Title:
Medigene's MDG1015, a Third-Generation TCR-T Therapy
Incorporating the PD1-41BB Costimulatory Switch Protein, Advancing
to the Clinic
The work to be presented will highlight the
Company’s lead candidate MDG1015, a first-in-class, third
generation T cell receptor engineered T cell (TCR-T) therapy
targeting NY-ESO-1/ LAGE-1a (New York oesophageal squamous cell
carcinoma 1 / L Antigen Family Member-1a), armored and enhanced
with the PD1-41BB costimulatory switch protein (CSP). A
first-in-human trial for MDG1015 is planned for gastric cancer,
ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma
with IND/CTA filing targeted for 2H 2024.
Oral presentation:
7th International Neoantigen Summit
2024 https://neoantigen-summit.com/Location: Hotel Novotel
Amsterdam City, Amsterdam Date and time: May 1, 2024, 12:00 – 12:30
pm local timePresenter: Dr. Giulia Longinotti, Director TCR
Discovery Platform Session: Illuminating Shared Neoantigen
Therapies to Induce More Durable & Robust Immunity in a Larger
Patient Population Title: KRAS Mutation-Specific TCR-T
Cells are Empowered for Improved Multi-Functionality &
Durability by Inclusion of a Costimulatory Switch
Protein
Dr. Longinotti will summarize the generation
process of optimal affinity 3S (sensitive, specific and safe) TCRs
targeting various Kirsten rat sarcoma virus specific mutations
(mKRAS), armored and enhanced with the PD1-41BB CSP. In vitro data
will showcase how armoring tools such as the PD1-41BB CSP can
enhance TCR-T cell functionality, and will also illustrate how the
composition of the drug product can be optimized for safety,
efficacy and durability.
--- end of press release ---
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology
platform company dedicated to developing differentiated T cell
therapies for treatment of solid tumors. Its End-to-End Platform is
built on multiple proprietary and exclusive technologies that
enable the Company to generate optimal T cell receptors against
both cancer testis antigens and neoantigens, armor and enhance
these T cell receptor engineered (TCR) -T cells to create
best-in-class, differentiated TCR-T therapies, and optimize the
drug product composition for safety, efficacy and durability. The
End-to-End Platform provides product candidates for both its own
therapeutics pipeline and partnering. Medigene’s lead TCR-T program
MDG1015 is expected to receive IND/CTA approval in the second half
of 2024. For more information, please visit. For more information,
please visit https://medigene.com/
This press release contains forward-looking
statements representing the opinion of Medigene as of the date of
this release. The actual results achieved by Medigene may differ
significantly from the forward-looking statements made herein.
Medigene is not bound to update any of these forward-looking
statements. Medigene® is a registered trademark of Medigene AG.
This trademark may be owned or licensed in select locations
only.
Medigene AG
Pamela Keck Phone: +49 89 2000 3333 01 E-mail:
investor@medigene.com
In case you no longer wish to receive any
information about Medigene, please inform us by e-mail
(investor@medigene.com). We will then delete your address from our
distribution list.